Citi Remains a Buy on Dexcom (DXCM)

In a report released on September 14, Joanne Wuensch from Citi reiterated a Buy rating on Dexcom. The company’s shares closed yesterday at $76.55.

Elevate Your Investing Strategy:

• Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

According to TipRanks, Wuensch is a 5-star analyst with an average return of 6.9% and a 62.58% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Medtronic, Tandem Diabetes Care, and Abbott Laboratories.

In addition to Citi, Dexcom also received a Buy from Piper Sandler’s Matthew O’Brien in a report issued on September 12. However, on September 8, Oppenheimer downgraded Dexcom (NASDAQ: DXCM) to a Hold.

DXCM market cap is currently $29.64B and has a P/E ratio of 52.91.

Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DXCM in relation to earlier this year. Last month, Mark Foletta, a Director at DXCM sold 195.00 shares for a total of $15,900.30.